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Abstract
Background: Rheumatoid arthritis (RA) treatment paradigms have shifted over the last two decades. There has
been increasing emphasis on combination disease modifying anti-rheumatic drug (DMARD) therapy, newer biologic
therapies have become available and there is a greater focus on achieving remission. We have evaluated the
impact of treatment changes on disease activity scores for 28 joints (DAS28) and disability measured by the health
assessment questionnaire scores (HAQ).
Methods: Four cross-sectional surveys between 1996 and 2014 in two adjacent secondary care rheumatology
departments in London evaluated changes in drug therapy, DAS28 and its component parts and HAQ scores (in
three surveys). Descriptive statistics used means and standard deviations (SD) or medians and interquartile ranges
(IQR) to summarise changes. Spearman’s correlations assessed relationships between assessments.
Results: 1324 patients were studied. Gender ratios, age and mean disease duration were similar across all cohorts.
There were temporal increases in the use of any DMARDs (rising from 61 % to 87 % of patients from 1996-2014),
combination DMARDs (1 % to 41 %) and biologic (0 to 32 %). Mean DAS28 fell (5.2 to 3.7), active disease (DAS28 >
5.1) declined (50 % to 18 %) and DAS28 remission (DAS28 < 2.6) increased (8 % to 28 %). In contrast HAQ scores
were unchanged (1.30 to 1.32) and correlations between DAS28 and HAQ weakened (Spearman’s rho fell from 0.56
to 0.44).
Conclusions: Treatment intensity has increased over time, disease activity has fallen and there are more remissions.
However, these improvements in controlling synovitis have not resulted in comparable reductions in disability
measured by HAQ. As a consequence the relationship between DAS28 and HAQ has become weaker over time.
Although the reasons for this divergence between disease activity and disability are uncertain, focussing treatment
entirely in suppressing synovitis may be insufficient.
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Background
Rheumatoid arthritis (RA) management paradigms have
changed over the last two decades. There is now greater
emphasis on intensive suppressive treatment with
greater use of disease modifying anti-rheumatic drugs
(DMARDs), including combinations of DMARDs, and
the use of biologic treatments when standard DMARDs
are insufficient [1]. The impact of treatment can be
assessed using standard methods such as the Disease
Activity Score for 28 joints (DAS28) [2] and the Health
Assessment Questionnaire Disability Index (HAQ) [3].
In recent years ‘Treat to Target’ has provided a manage-
ment framework. It emphasises that the treatment goal
should be achieving remission [4]. Several groups have
shown that the frequency of severe disease is declining
and there are growing numbers of patients with
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moderate or low DAS28 scores [5–8]. Despite these
findings, studies from the Netherlands have suggested
that although disease activity levels have improved over
time, levels of disability may actually be increasing [9].
We consider further information is needed about the
changing patterns of DAS28 and HAQ scores in RA
patients seen in routine treatment settings over the last
20 years. We have undertaken such an evaluation in two
adjacent English rheumatology units over two decades
examining the changes in treatment, disease activity and




Cross-sectional data were collected at four time points
from secondary care rheumatology departments at King’s
College Hospital and University Hospital Lewisham; these
are two adjacent centres in South London. The data
were collected prospectively by different trained clini-
cians using standardised clinical assessments in: (i)
1996-97; (ii) 2001-3; (iii) 2009-10; (iv) 2013-14. The
surveys assessed consecutive consenting outpatients at-
tending specialist rheumatology clinics within routine
clinical care settings.
Patients
The hospitals serve ethnically diverse inner city popula-
tions with broad ranges of social and financial status.
Patients included had a consultant diagnosis of RA by the
1987 criteria of the American College of Rheumatology.
Disease duration was calculated from date of rheumatolo-
gist diagnosis.
Data for the first three cohorts were collected as sur-
veys undertaken as part of routine care evaluations;
these have been previously published [10–12]. The
patients were consecutive outpatient attenders; there
were no exclusion criteria. Only patients in whom full
data for DAS28 components had been collected were
studied; this meant excluding 3 % of the previously
reported patients. Data for the fourth cohort were
extracted from routinely captured clinic attendance elec-
tronic patient records; full data was available during the
survey period in 520 RA patients from 1200 attenders
with inflammatory arthritis.
Assessments
The data collected comprised demographic details (age,
sex and disease duration), information about disease
activity including the disease activity score for 28 joints
(DAS28) and its component parts with ESR, and the
use of synthetic DMARDs, biologic DMARDs and oral
steroids. We also collected information about disability
scores using the Health Assessment Questionnaire
(HAQ), pain (100 mm visual analogue scores) and fa-
tigue (100 mm visual analogue scores) completed by
the patients were collected in the first, second and
fourth cohorts (for pain) and second and fourth cohort
(for fatigue). HAQ scores, pain VAS and fatigue mea-
sures were not collected in the third cohort. Patients
were assessed prospectively by medical and nursing
staff who had been trained in RA assessments.
Analysis
Statistical analysis used STATA statistical software (ver-
sion 13). Age, disease duration, disease activity assess-
ments and other outcomes were described using means
and standard deviations (SD) or medians and interquartile
ranges (IQR) for non-normal data. DAS28 category pro-
portions were given as raw figures and percentages.
DAS28 remission was defined as a score of <2.6, low dis-
ease activity 2.6 – 3.2, moderate disease activity 3.2 – 5.1,
sever disease >5.1. Spearman’s correlations were used to
assess relationship between the DAS28 and HAQ.
Local approvals
Collecting data for the first cohort received approval
from King’s College Hospital Local Research Ethics
Committee; patients provided written informed consent.
The third and fourth cohorts utilised data collected
through departmental audits. Approval for these collec-
tions was obtained from the Trust audit division. All
data was anonymised before analysis. No additional data
were collected from patients for the purpose of the
current study. As the analysis was the secondary use of
existing anonymised data our local research and devel-
opment office approved its use in line with current
national research governance arrangements.
Results
The four cohorts of RA patients seen between 1996 and
2014 ranged in size from 189 to 520 patients. Overall
1324 patients were studied. The groups had similar
demographic features (Table 1): 76-80 % were female;
their mean ages were 58-60 years; and their mean dis-
ease durations were 9.1-10 years.
Over time more patients received suppressive therapy:
in 1996-97 only 61 % of patients received one or more
DMARDs; by 2013-14 87 % of patients were receiving
them (Table 1). The intensity of suppressive treatment
increased over time, with rising numbers of patients
receiving combination DMARDs and biologics. Combin-
ation DMARD use was 1 % in 1996-97 and increased to
41 % by 2013-14. No biologics were available in 1996-97;
their use increased from 4 % in 2001-03, 17 % in 2009-10
and further still to 32 % in 2013-14. In contrast, systemic
steroid use was unchanged.
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Disease activity fell over time, with the proportion of
patients in remission increasing from 8 % in the earliest
cohort to 28 % in the most recent (Table 2). In parallel,
the proportion with severe disease fell from 50 % in the
earliest cohort to 18 % in the most recent, whilst the
proportion with moderate disease remained constant.
There are differences in the relative contribution of the
individual components of DAS28 across disease activity
strata (Table 2). Most noticeable are the reductions in
swollen joint counts in all strata compared with the
increases in patient global scores in most strata. The
mean pain VAS improved with each consecutive cohort
from 50 in 1996-97, 48 in 2001-03, and 44 in 2013-2014
but mean fatigue scores did not fall (see table).
In contrast to measures of disease activity, there was no
evidence of a fall in disability levels over time. Mean HAQ
scores were 1.30 in 1996-97 and 1.32 in 2013-14, with a
slightly higher mean HAQ of 1.52 in 2001-03. Comparing
disability change over time across the disease activity
groups, mean HAQ scores in patients in remission and
low disease activity states were higher in 2013-14 com-
pared to 1996-97 (Table 2). Associated with this finding
the overall correlation between disease activity and disabil-
ity became weaker over time; in 1996-97 Spearman’s rho
was 0.56, in 2001-03 it was 0.55 and in 2013-14 it was 0.44.
Discussion
Our consecutive cross-sectional surveys across two collab-
orating adjacent specialist units in London between 1996
and 2014 showed the changing pattern of RA treatment
and disease severity. The key changes were: increases in
the use of DMARDs, combination DMARDs and bio-
logics; falls in mean DAS28; and increases in DAS28
remissions. However, HAQ scores were unchanged and
correlations between DAS28 and HAQ weakened. The
age, gender and disease duration of the four cohorts were
similar and consequently changes in DAS28 could not be
explained by differences in demographic factors.
There are several possible explanations for the decline
in disease severity: RA may be becoming a milder dis-
ease; milder cases of RA may be attending outpatient
clinics; or RA treatments are becoming more effective.
We noted a minor non-significant difference in disease
durations in the last two cohorts compared with earlier
cohorts (increasing from 8 years to 10 years). We cannot
be certain that this did not have some impact on disabil-
ity levels but it is unlikely to have been substantial.
Our findings suggest a trend towards milder RA. This
has been highlighted in studies of inception cohorts of
RA patients [13–16]. Similar reduction in disease activity
levels have also been described in established RA, and
these reductions preceded the introduction of biologic
agents [6]. There are several possible explanations for
these observed declines in disease severity. Firstly RA
may be becoming a milder disease. Secondly, milder
cases of RA may be attending outpatient clinics. Finally
RA treatments may be becoming more effective. A
North American analysis of patients seen over three con-
secutive decades from 1970 suggested the reduction in
disease severity could be explained entirely by adjusting
for DMARD exposure, indicating increased treatment
accounts for the improvement [8]. Irrespective of why
Table 1 Characteristics of patient cohorts
Characteristic 1996-97 2001-03 2009-10 2012-14
n = 189 n = 310 n = 304 n = 520*
Female gender, n (%) 140 (74 %) 237 (76 %) 244 (80 %) 413 (79 %)
Age, mean (SD) 59 (14) 60 (13) 59 (15) 58 (15)
Disease duration in years, median (IQR) 8 (13) 9 (10) 10 (9) 10 (9)
Any DMARD, n (%) 115 (61 %) 199 (64 %) 242 (80 %) 420 (87 %)
Combination DMARDs, n (%) 1 (1 %) 31 (10 %) 65 (21 %) 199 (41 %)
Biologic users, n (%) 0 11 (4 %) 53 (17 %) 155 (32 %)
Oral steroids, n (%) 23 (12 %) 70 (23 %) 30 (10 %) 56 (12 %)
DAS, mean (SD) 5.2 (1.6) 4.7 (1.6) 3.8 (1.5) 3.7 (1.6)
Tender joint count, mean (SD) 10.1 (9.2) 7.5 (7.3) 4.1 (5.6) 4.2 (6.2)
Swollen joint count, mean (SD) 7.1 (5.5) 4.8 (4.1) 2.9 (4.2) 1.5 (2.7)
Patient global, mean (SD) 50 (25) 50 (29) 40 (25) 35 (28)
ESR, mean (SD) 35 (26) 33 (27) 26 (21) 19 (21)
HAQ score, median (IQR) 1.30 (1.52) 1.52 (0.79) Not available 1.32 (0.84)
Pain, Mean (SD) 50 (24) 48 (28) Not available 44 (28)
Fatigue, Mean (SD) Not available 50 (28) Not available 51 (26)
Legend: SD standard deviation, IQR interquartile range, *n = 484 for DMARD data
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fewer patients have highly active RA, its impact is reflected
by declining rates of hand and foot surgery for RA [17].
Studying the DAS28 strata in the different cohorts
showed differences over time between subjective and
objective components of DAS28. Swollen joint counts
fell but patient global responses did not. Composite
measures like DAS28 are influenced by many factors in
addition to the inflammatory burden of RA. These other
factors include comorbidity, especially psychological
problems such as depression, and other features of the
disease such as pain [18]. The fact that swollen joint
counts have fallen so substantially across all disease
activity strata implies that the control of synovitis by
modern treatment is more effective than would appear
to be the case from DAS28 scores alone. The most
prevalent RA state under follow up in contemporary
practice is moderately active disease, which accounted
for 41 % of the most recent cohort, and an evidence-
based management strategy is needed for this group.
Throughout the time of the four cross sectional surveys,
there was greater emphasis on the use of DMARDs,
DMARD combinations and biologics. There has also been
an increase in the involvement of specialist nurses. We
consider these developments are the most likely explan-
ation of these changes. The greater emphasis on seeing
RA patients early may also have influenced the findings.
However, the introduction of formal early arthritis clinics
in both centres did not occur until after the last survey
was completed.
The relationship between disease activity and disability
has been studied in detail in historic cohorts, where it was
apparent that disease activity was the key driver of disabil-
ity in early disease, whilst erosive damage became more
important in established disease [19]. However, in an era
of diminishing erosive damage, the relationship between
disease activity and disability may have changed. A longi-
tudinal analysis of the Nijmegen inception cohort actually
revealed increasing levels of disability over time [9]. UK
data from the Norfolk Arthritis Register (NOAR) revealed
similar findings, with increasing levels of reported disabil-
ity over time, despite reductions in measured disease
activity [13]. Of even more relevance is an analysis com-
bining the NOAR cohort with another UK inception
cohort that explored HAQ progression over time [16].
Several distinct trajectories were noted; these were pre-
dicted by older age, female sex, longer symptom duration,
higher DAS28 and lower social class.
Our findings help contextualise the changes in HAQ
over time. Whilst we observed an overall reduction in dis-
ability, this was possibly driven by a decline in patients
Table 2 Comparison of DAS28 components and disability status across disease activity strata
DAS28 Group <2.6 2.6 – 3.2 3.2 – 5.1 >5.1
1996-97 Cohort
Number of patients, (%) 15 (8 %) 8 (4 %) 72 (38 %) 94 (50 %)
Tender joint count, mean (SD) 0.7 (1.4) 0.8 (1.4) 4.9 (4.8) 16.4 (8.5)
Swollen joint count, mean (SD) 0.3 (0.9) 4.0 (3.6) 4.5 (3.3) 10.5 (5.1)
Patient global, mean (SD) 14 (7) 26 (16) 42 (20) 64 (21)
ESR, mean (SD) 12 (7) 15 (8) 30 (27) 44 (25)
HAQ, mean (SD) 0.3 (0.4) 0.8 (0.8) 1.0 (0.8) 1.7 (0.8)
2001-03 Cohort
Number of patients, (%) 29 (9 %) 32 (10 %) 115 (37 %) 135 (43 %)
Tender joint count, mean (SD) 0.4 (0.7) 1.3 (1.6) 4.6 (4.2) 12.9 (7.1)
Swollen joint count, mean (SD) 0.8 (1.4) 2.3 (2.6) 3.5 (2.8) 7.5 (4.0)
Patient global, mean (SD) 15 (19) 28 (22) 42 (22) 70 (22)
ESR, mean (SD) 9 (7) 20 (19) 26 (21) 48 (28)
HAQ, mean (SD) 0.7 (0.7) 1.0 (0.7) 1.4 (0.7) 1.9 (0.6)
2013-14 Cohort
Number of patients, (%) 148 (28 %) 67 (13 %) 212 (41 %) 93 (18 %)
Tender joint count, mean (SD) 0.7 (1.6) 1.6 (2.4) 4.7 (4.7) 15.2 (7.9)
Swollen joint count, mean (SD) 0.2 (0.7) 1.0 (1.6) 1.9 (2.3) 5.3 (3.6)
Patient global, mean (SD) 24 (17) 24 (17) 50 (21) 73 (16)
ESR, mean (SD) 9 (7) 22 (17) 26 (18) 34 (23)
HAQ, mean (SD) 0.9 (0.8) 1.2 (0.8) 1.4 (0.8) 1.9 (0.6)
Legend: SD standard deviation
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with severe disease. In contrast, HAQ scores increased
within the lower DAS28 groups. This corresponds to the
rise in the subjective components of DAS28, which pre-
dictably correlate better with patient reported disability.
One explanation for these findings is that background
levels of disability might be rising, perhaps due to external
factors such as the climbing levels of obesity in the general
population. However, this is at odds with data from non-
RA populations that have reported reductions in disability
in the general population [20]. An alternative explanation
is that way patients complete HAQ scores may be chan-
ging: patients might report disability differently using the
HAQ due to higher expectations. The HAQ tool is also
limited by floor and ceiling effects. Irrespective of the rea-
son for the changing pattern of HAQ score, it remains a
core metric by which effectiveness of RA treatments are
judged [21].
Our study has several strengths. We have reported real
time data with no exclusion criteria which is likely to be
highly representative of RA patients seen in outpatient
clinics at the time of each survey. It was also sufficiently
large to provide robust assessments of treatment and
disease activity. Our study does however have some limi-
tations. The data were collected at consecutive cohorts
was cross sectional and did not capture the same
patients. As the data collected were anonymized we were
uncertain if some patients contributed to more than one
cohort. The assessments were carried out by a number
of different physicians over the four time periods and
there might have been variations in the way individual
clinicians assess joint counts. It is also possible that the
pattern of follow up in clinics has changed with RA
patients who have milder disease being more frequently.
Another possibility is that there may have been changes
in the level of background disease activity in patients
seen in specialist clinics. These are inherent problems in
all studies that evaluate temporal changes in disease
activity.
Conclusions
Over the last two decades the management of rheumatoid
arthritis has changed. Patients are treated more intensively
with both conventional DMARDs and biologics. Disease
activity levels have fallen and more patients achieve remis-
sion; however, as only a minority of patients are in remis-
sion there is still substantial room for improvement. The
failure to substantially reduce disability levels is of some
concern. It is possible that focusing on reducing disease
activity has less impact on disability than was previously
considered. It may be particularly important to focus on
reducing tender joint counts and patient global assess-
ments, which may be related to non-inflammatory aspects
of RA. Finally, further work is needed to understand how
to best manage moderate RA, the phenotype that now
makes up the largest burden of clinic attenders.
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